This systematic review evaluates the efficacy of recently approved drugs for dyslipidemia, including bempedoic acid, evolocumab, alirocumab, and inclisiran, in reducing LDL-C and apolipoprotein-B levels. This evidence concerns the gene COG2 and metabolic syndrome.